Evinacumab Gets Priority Review for Homozygous Familial Hypercholesterolemia
Evinacumab is an investigational fully-human monoclonal antibody that binds to and blocks the function of angiopoietin-like 3 (ANGPTL3).
Dyslipidemia
LDL-C Lowering Combo Therapy Nexlizet Now Available
Nexlizet (bempedoic acid and ezetimibe; Esperion) is now available for use as an adjunct to diet and maximally tolerated statin therapy for the treatment of adults with heterozygous familial hypercholesterolemia or established atherosclerotic cardiovascular disease who require additional lowering of LDL-C.
Nexletol, a First-in-Class LDL-C Lowering Oral Therapy, Now Available
Bempedoic acid is a first-in-class adenosine triphosphate-citrate lyase (ACL) inhibitor that lowers LDL-C by inhibiting cholesterol synthesis in the liver.
Study Shows Evolocumab Significantly Reduces LDL-C in Adults With HIV
“This is the first phase 3 study to demonstrate that a PCSK9 inhibitor can effectively and safely reduce LDL-C in people living with HIV at risk for cardiovascular disease who have high cholesterol level despite statin treatment,” said Professor Franck Boccara, MD, PhD, cardiologist and primary study investigator.
AHA: Prescription Omega-3 Fatty Acids Effectively Lower Triglycerides
4 g daily EPA+DHA or EPA only effective and safe for use as monotherapy or in combination
High Discordance Between LDL-C, Lp(a) Reduction in Response to Evolucumab
There is a high prevalence of discordance in the reduction of low-density lipoprotein cholesterol (LDL-C) and lipoprotein(a) (Lp[a]) in response to evolocumab treatment.
Praluent Soon to Be Available at Reduced Price
Regeneron and Sanofi announced that both doses of Praluent (alirocumab) will be made available at a new US list price—60% lower than the original—in early March.
Cost-Effectiveness of Alirocumab vs Ezetimibe Added to Statin Examined
Price of alirocumab would have to decrease from original cost of 14,560 to 1,974 to be cost-effective
Two PCSK9 Inhibitors for LDL Cholesterol Promising in Studies
Evolocumab and alirocumab, monoclonal antibodies that inhibit proprotein convertase subtilisin-kexin type 9 (PCSK9), reduce low-density lipoprotein (LDL) cholesterol levels in the longer term, according to two studies published in the New England Journal of Medicine.
Dyslipidemia Drug Indications
Comparative chart of single and combination treatment options indicating which lipids can be targeted for dyslipidemias.
